| SAREPTA THERAPEUTICS |
| USA |
| Gesundheit |
| US8036071004 / A1J1BH |
| AB3A (Frankfurt) / SRPT (NASDAQ) |
| FRA:AB3A, ETR:AB3A, AB3A:GR, NASDAQ:SRPT |
| - |
| https://www.sarepta.com/ |
|
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes appro..
>Volltext.. |
| 1453.93 Mio. EUR |
| 1785.19 Mio. EUR |
| 1894.16 Mio. EUR |
| 55.66 Mio. EUR |
| -55.78 Mio. EUR |
| -0.49 EUR |
| 899.01 Mio. EUR |
| 402.78 Mio. EUR |
| 137.21 Mio. EUR |
| 1.31 |
| -8.43% |
| 75.75% |
| - |
| - |
| - |
| - |
| SAREPTA, AVI BIOPHARMA |
| 06.08.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|